While these proteins do not reside in the secretory pathway and are not likely to be BiP clients, it is certainly feasible that differences in their protein levels represent secondary and/or tertiary consequences of SIL1 loss, which in turn contribute to the diverse neurological symptoms that are associated with MSS with varying penetrance. The gene discussed is SIL1; the disease is Marinesco-Sjogren syndrome.